logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8859468 B1

PDFFull Text
Date of Patent:
Oct. 14, 2014

Filed:

Mar. 11, 2011

Hypermethylation biomarkers for detection of cervical cancer

Applicants:

Rafael Enrique Guerrero-preston, Baltimore, MD (US);

David Sidransky, Baltimore, MD (US);

Priscilla Brebi-mieville, Pitrufquen, CL;

Inventors:

Rafael Enrique Guerrero-Preston, Baltimore, MD (US);

David Sidransky, Baltimore, MD (US);

Priscilla Brebi-Mieville, Pitrufquen, CL;

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:

Johns Hopkins Technology Transfer

Primary Examiner:

Jennifer McDonald

Assistant Examiner:

Valerie Toodle

Int. Cl.
CPC ...
C40B 30/04 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 2600/154 (2013.01); C12Q 1/6869 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

Pap smears and HPV infection tests do not distinguish between lesions that will progress to an invasive carcinoma and those that will not. We aimed to identify epigenetic biomarkers for diagnosis and progression monitoring of premalignant lesions in cervical cancer. Hypermethylated genes were identified as potential biomarkers after validation by MSP, including GGTLA4 and ZNF516. The methylation frequency for these two genes was higher in tumor: GGTLA4 (100%) and ZNF516 (96%); than in normal samples: GGTLA4 (12%) and ZNF516 (16%). The methylation status of GGTLA4 showed a progression in methylation frequency from normal samples to invasive carcinoma. The immunohistochemical expression was lower in tumor for both: GGTLA4 (50.8%) and ZNF516 (66.2%); than in normal samples: GGTLA4 (71.2%) and ZNF516 (88.1%) (p<0.05). In conclusion, we identified methylation biomarkers for the molecular screening and characterization of cervical cancer.

Find Patent Forward Citations

Guerrero-Preston, Rafael. (2014). Hypermethylation biomarkers for detection of cervical cancer (U.S. Patent No. 8859468). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/8859468

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…